M&A Deal Summary |
|
|---|---|
| Date | 2016-08-08 |
| Target | Scandinavian Micro Biodevices ApS |
| Sector | Medical Products |
| Buyer(s) | Zoetis |
| Deal Type | Add-on Acquisition |
| Deal Value | 80M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1952 |
| Sector | Life Science |
| Employees | 13,800 |
| Revenue | 9.3B USD (2024) |
Zoetis engages in the discovery, development, manufacture and commercialization of a diverse portfolio of animal health medicines and vaccines designed to meet the real-world needs of veterinarians and the livestock farmers and companion animal owners they support. Zoetis was founded in 1952 and is based in Parsippany, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 13 |
| Sector: Medical Products M&A | 2 of 3 |
| Type: Add-on Acquisition M&A Deals | 5 of 12 |
| Country: Denmark M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
| Size (of disclosed) | 5 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-11-10 |
PHARMAQ Holding AS
Overhalla, Norway PHARMAQ Holding AS is a pharmaceutical company focused on aquaculture. It develops, manufactures and markets vaccines and therapeutic products for the prevention and treatment of diseases in farmed fish. |
Buy | $765M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-04-13 |
Nexvet Biopharma
Tullamore, Ireland Nexvet Biopharma PLC is a veterinary biologic therapeutics company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet Biopharma is based in Tullamore, Ireland. |
Buy | $85M |
